Institute of AI for Health and Munich Leukemia Laboratory announce research collaboration

The Institute of AI for Health (AIH) and the Munich Leukemia Laboratory (MLL) have agreed on a comprehensive research and development cooperation. The main goal is the implementation of machine learning and artificial intelligence (AI) in various areas of leukemia diagnostics to promote scientific progress and improve patient treatment.

AIH researchers have deep know-how and long standing experience in the field of machine learning and data science, while the MLL contributes with its extensive diagnostic and clinical databases as well as its medical-diagnostic expertise. Both partners see high synergistic potential for the joint further development of increasingly data-driven leukemia diagnostics. 

"Based on our  very successful collaboration projects to date and in view of the great expertise of both partners in their core competencies, the agreement on a long-term collaboration in the field of leukemia diagnostics is a very natural next step," says Professor Torsten Haferlach, one of the managing directors and founders of MLL. "In routine diagnostics alone, we generate gigantic amounts of data every day. The systematic evaluation and recognition of patterns in this data is only conceivable with the help of AI-based methods. In this respect, we consider ourselves fortunate to have an extremely strong partner for this endeavour at our side in the AIH of Helmholtz Zentrum München."

Carsten Marr, director of the AIH, adds: "With extensive data and unique expertise, MLL is the perfect partner for us to advance our AI-based leukemia diagnostics. We are building on an already trusted collaboration and aim to bring our algorithms to scale with MLL. We are convinced that our collaboration will translate into tangible benefits for patients."

The Institute of AI for Health and the Munich Leukemia Laboratory are enthusiastic about this cooperation and working towards real-world clinical solutions.